20:11 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868. In exchange for the compound,...
19:38 , Feb 27, 2019 |  BC Extra  |  Company News

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868. In exchange for the compound,...
00:47 , Feb 16, 2019 |  BC Extra  |  Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
22:55 , Feb 8, 2019 |  BC Extra  |  Company News

Management tracks: Takeda’s Plump becomes president of R&D

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) Andrew Plump has become president of R&D, according to the pharma's website. He was Takeda's CMO and CSO since 2015. Wolfram Nothaft, former head of global clinical development at...
21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
22:56 , Jan 25, 2019 |  BioCentury  |  Finance

Venrock spreads HAE bets

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II...
21:43 , Jan 18, 2019 |  BioCentury  |  Product Development

ImmunoGen’s milestone year

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data from its lead...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
18:12 , Jan 11, 2019 |  BC Week In Review  |  Company News

Takeda divesting $10B in non-core assets following completed Shire acquisition

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Jan. 7 that it completed its acquisition of Shire plc (Dublin, Ireland). At the J.P. Morgan Healthcare Conference on Jan. 8 to discuss the acquisition, Takeda President and CEO...